AbbVie received final approval from the European Commission for its acquisition of Allergan.
Citing market conditions, Bausch Health made a series of moves to keep its debt at current levels.
A Utah gastroenterologist has agreed to pay the HHS’ Office of Civil Rights $100,000 for a corrective action plan related to a potential violation of a HIPAA security rule.
Takeda Pharmaceuticals continued to combat its Shire acquisition-related debt by selling off non-core assets to Hypera in Brazil. Takeda then dipped into its pool of non-core assets again and sold $660 million to Stada Arzneimittel.
On top of that, Takeda reached a deal to acquire PvP Biologics after the company reports results from its phase 1 proof-of-mechanism study of its treatment for uncontrolled celiac disease.
The FDA awarded Pavmed’s EsoGuard Esophageal DNA Test breakthrough device designation to aid in diagnosing Barrett’s esophagus.
Orlando, Fla.-based Digestive and Liver Center of Florida implemented AndorHealth’s ThinkAndor, an internal communication and collaboration tool that interprets EHR systems and presents information in a more easily interpretable format.
More articles on surgery centers:
3 ways to improve ASC revenue cycle performance
Indiana legislators meet resistance on price transparency bill
Maximizing reimbursements in ASCs: A review of reimbursement methodology
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.